Medicare spending on newly approved Alzheimer’s drugs Leqembi and Kisunla is tracking far below earlier projections, according to a CMS spokesperson cited by STAT+. Uptake has been so muted that Medicare is not forecasting significant spending in 2026 or 2027, a sharp reversal from prior expectations that it would spend billions annually, including billions for Leqembi alone. Clinicians and Medicare experts attributed the lower uptake to real-world barriers: intravenous administration, heavy imaging requirements, a smaller eligible patient population, and concerns about limited meaningful benefits alongside risks such as severe brain bleeding. The reporting adds an immediate payer-facing perspective on how adoption hurdles—delivery logistics and clinical risk-benefit constraints—can rapidly reshape projected market size even after regulatory approval.